Overview
International Journal of Biological and Drug Research (IJBDR) is a publisher of open-access journals. All submitted manuscripts are managed by Manuscript Peer-Review Process a rapid and rigorous double-blind peer-reviewed, manuscript handling, and editorial process. In this platform, all authors, reviewers, editors, and editorial office work on a single platform.
Submission Checklist
A manuscript submission checklist is necessary during the final submission of an article before sending it to the journal for the peer-review process.
Manuscript Submission Process
All manuscripts must be submitted online at www.ijbdr.com. The submitting author, who is generally the corresponding author, is responsible for the manuscript during the submission and peer-review process. The submitting author must ensure that all eligible co-authors have been included in the author list read the authorship qualify criteria and that they have all read and approved the submitted version of the manuscript, To submit your manuscript, first-time users click the register button from the submission portal. On successful registration, you will receive an email verification mail and after confirmation, you will be able to log in as an author you can directly log in by using your credentials (Username-Registered mail ID & Password)
After successful registration, log in as an author and post your manuscript for further processing.
Manuscript Preparation
Cover Letter
Cover Letters must be included with each manuscript submission. The cover letter should prove the following details:
Manuscript Title
The title of your manuscript should be concise, specific, relevant, and informative that contain the major keywords, formulae, and abbreviations avoided.
Type of Manuscript
Original Research Article
The manuscript should be typed, 2 spaced on standard A4 sized sheets (8.3" x 11.7") with 1" margins on all sides. The manuscript shall be prepared in Times New Roman using a font size of 12 and title shall be, Bold. All section titles in the manuscript shall be in font size 12, bold and subtitles in each section shall be in font size 12, bold Sentence case. Illustrations (Figures & Tables) should be presented at the end of manuscript with proper citations in the manuscript. Standard International Units should be used throughout the text. Pages should be numbered consecutively. The fonts used in the text as well as graphics should be restricted to Times New Roman along with standard symbols.
Abstract
The abstract of Research article should contain 250-300 words and should be prepared using IMRAD structure and should be divided in Introduction, Materials & methods, Results,Discussion and Conclusion. Reviews and mini reviews also require an abstract which may or may not be structured.
Introduction
Introduction should state the specific purpose or research objective of, or hypothesis tested by, the study or observation. Only directly pertinent references should be cited and do not include data or conclusions from the work being reported. It should be brief and concisely indicate the aim of the study and the essential back ground information. Introduction should clearly state the hypothesis or purpose statement, how and why the purpose or hypothesis was developed and why the author deems it important.
Materials and methods
This part should be as clear as possible to allow the other researchers to reproduce the experimental outcomes. Concise and complete information about the material (Capitalize the trade names and also include the manufacturer's name and address) and the analytical, statistical and experimental procedures used should be provided. All the experimental procedures should be described in details with proper citation of previously published procedures. Methods in general use need not be described in detail. Important modifications of published procedures should be mentioned briefly. Use of sub-headings is encouraged to divide the segment. Primary headings should be in bold, UPPER CASE or CAPITAL LETTERS. Secondary or subheadings should be bold, Sentence case. Further subheadings should be in Italicized sentence case. In case of animal/human experiments or clinical trials authors must give the details of ethical approval clearly mentioning the Approval number and year of approval.
Results and Discussion
After careful observation of experimental data and statistical applications (wherever applicable) results and their significance should be presented clearly and concisely, preferably in the form of graphs, figures and tables which should be self explanatory. Data already presented in the tables must not be repeated in figures or vice versa. Discussion should be based on critical review of the results in the light of relevant literature and should relate the results to current understanding of research problems under investigation.
Conclusion
It should state clearly the main conclusions of the research study highlighting its importance and relevance. Summary illustrations can also be used.
Acknowledgement
All the Acknowledgements should be presented in a separate section after the conclusion. If external funding has been obtained for the study, then that should be mentioned under a separate header "Funding", after the acknowledgements. The authors must declare all sources of funding received for the research submitted to the journal. Authors should give the name of granting agencies and grant numbers, along with a short description of each funder’s role.
References
All the references should be cited in the text designated by square brackets after the punctuation marks. The style and punctuation of the references should confirm to the following examples:
Journal references
Srivastav RK, Ansari TM, Prasad M, Vishwakarma VK, Upadhyay PK, Ahsan F, Shamim A. An inquest into regulatory mechanism of caveolin by ischemic preconditioning against orchidectomy-challenged rat heart. Mol Cell Biochem. 2021;476(7):2587-2601.
References to Books
Patents
Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1.
Websites
Singh G, Varshney V, Goyal A, Ali N, Iqbal M, Kaur I, Vargas-De-La-Cruz C, Behl T. Chrysin restores the cardioprotective effect of ischemic preconditioning in diabetes-challenged rat heart. Heliyon. 2023;9(11):e22052. PubMed PMID: 38027733.
Kaur R, Singh S, Sood P, Singh S, Banerjee S, Singh TG. Diabetic cardiomyopathy: Mechanistic insights on molecular pathways and emerging therapeutic approaches. Heart Fail Rev. 2025;30(6):1443-1480. doi: 10.1007/s10741-025-10562-7. PubMedPMID: 41015637.
For other types of citation, please see "Uniform Requirement for Manuscripts Submitted to Biomedical Journals: Sample References" at https://www.nlm.nih.gov/bsd/uniform_requirements.html
Conflict of interest (COI)
All the authors are required to disclose the possible conflicts of interest/ Competing Interests they may have with publication of the manuscript or an institution or product that is mentioned in the manuscript and/or is important to the outcome of the study presented. Authors should also disclose conflict of interest with products that compete with those mentioned in their manuscript. The Conflict of Interest statement should list each author separately by name.
Tables & Figures
Tables, figures and graphs should not be embedded within the manuscript, but should be included at the end of the manuscript on separate pages. Tables should be created using MS-Word processor and cited consecutively in the text. All Captions/legends will be placed below figures and adjusted to 10 font size. The title of table should be typed at the top of the table in the sentence case format. Any footnote should be typed at the bottom of the table in italic. To ensure the highest print quality, your figures must be submitted in TIF/JPEG format with minimum 300 dpi or higher resolutions.
Ethical Approvals (if applicable)
Patient Rights
Patients have a right to privacy, thus all the studies including humans should be conducted with informed consent. Publication should not contain any identifying information of the subjects in written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. When informed consent has been obtained, it should be indicated in the article. Investigations with human subjects must follow the ethical standards formulated in the Helsinki Declaration of 1964, revised in 2000. All the experiment should be approved by the institutional human experimentation committee or equivalent.
Animal Rights
Animal experiments must follow the ethical standards for the care and use of laboratory animals. Article involved the animal experiments must seek approval from the Institutional Ethical Committee in accordance with "Principles of Laboratory Animal Care" (NIH publication no. 85-23, revised 1985).
Clinical trial registry
The authors are advised to register for the clinical trials with a clinical trial registry that allows free online access to public. Registration in the following trial registers is acceptable:
Clinical Trial Registry India, Netherlands Trial Register, UMIN Japan, NHMRC Australia, US-NLM, ISRCTN registry and other recognized institutions.
Abbreviations
Only Internationally accepted standard abbreviations should be used throughout the manuscript. All nonstandard abbreviations should be kept to a minimum and must be defined in the text following their first use.
Review Articles
Review articles should not be more than 20 pages and contain exhaustive and comprehensive coverage of relevant literature. Review articles should preferably be written by scientists who have in-depth knowledge of the topic. All formatting requirements for Review articles are similar to those applicable to Research articles.
Structure: Abstract, Keywords, Introduction, Discussion, Conclusion and References
Short Communications
IJBDR is open to interesting scientific results worthy of publication without requiring extensive introduction and discussion. This section should be organized as follows: Abstract, Introduction, Materials and methods, Results and discussion (combined). Not more than 10 references should be provided. Tables, figures and references are to be arranged in the same way as for research papers.
Symbols and abbreviations
Unless specified otherwise, all temperatures are understood to be in degrees centigrade and need not be followed by the letter ‘C’. Abbreviations should be those well known in scientific literature. In vitro, in vivo, insitu, ex vivo, ad libitum, et al. and so on are two words each and should be written in italics. None of the above is a hyphenated word. All foreign language (other than English) names and words shall be in italics as a general rule. General Guidelines for units and symbols.
| Symbol / Abbreviation | Full Form / Meaning | Unit (if applicable) |
|---|---|---|
| % w/v | Percentage weight per volume | – |
| % v/v | Percentage volume per volume | – |
| °C | Degree Celsius | Temperature |
| µg | Microgram | 10−6 g |
| µL | Microlitre | 10−6 L |
| µM | Micromolar | mol·L−1 |
| AUC | Area Under the Curve (pharmacokinetics) | – |
| ATP | Adenosine Triphosphate | – |
| BP | Blood Pressure | mmHg |
| BSA | Bovine Serum Albumin | – |
| CI | Confidence Interval | – |
| CL | Clearance (pharmacokinetics) | L·h−1 |
| DNA | Deoxyribonucleic Acid | – |
| EC50 | Half Maximal Effective Concentration | mol·L−1 |
| ELISA | Enzyme-Linked Immunosorbent Assay | – |
| FDA | Food and Drug Administration | – |
| FID | Flame Ionization Detector | – |
| HPLC | High-Performance Liquid Chromatography | – |
| HR | Hazard Ratio | – |
| IC50 | Half Maximal Inhibitory Concentration | mol·L−1 |
| IV | Intravenous | – |
| LD50 | Median Lethal Dose | mg·kg−1 |
| LC-MS | Liquid Chromatography–Mass Spectrometry | – |
| LOD | Limit of Detection | – |
| LOQ | Limit of Quantification | – |
| MIC | Minimum Inhibitory Concentration | µg·mL−1 |
| NMR | Nuclear Magnetic Resonance | – |
| OD | Optical Density | – |
| PBS | Phosphate-Buffered Saline | – |
| PK | Pharmacokinetics | – |
| QC | Quality Control | – |